Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial in emergent neuroendocrine Prostate cancer (combination therapy) in the US

Trial Profile

Phase I trial in emergent neuroendocrine Prostate cancer (combination therapy) in the US

Planning
Phase of Trial: Phase I/II

Latest Information Update: 05 Nov 2018

At a glance

  • Drugs Pembrolizumab (Primary) ; Talabostat (Primary)
  • Indications Prostate cancer
  • Focus Adverse reactions; First in man
  • Most Recent Events

    • 05 Nov 2018 According to BioXcel Therapeutics media release, the U.S. FDA has approved the Investigational New Drug (IND) application for BXCL701 in combination with pembrolizumab. Data readouts from the trial are expected throughout 2019.
    • 16 Oct 2018 New trial record
    • 08 Oct 2018 According to BioXcel Therapeutics media release, company announced it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration to evaluate its lead immuno-oncology candidate, BXCL701, in combination with pembrolizumab (Keytruda) as a potential therapy for treatment emergent neuroendocrine prostate cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top